Author:
Karmakar Malancha,Ragonnet Romain,Ascher David B.,Trauer James M.,Denholm Justin T.
Abstract
Abstract
Background
Antimicrobial resistance develops following the accrual of mutations in the bacterial genome, and may variably impact organism fitness and hence, transmission risk. Classical representation of tuberculosis (TB) dynamics using a single or two strain (DS/MDR-TB) model typically does not capture elements of this important aspect of TB epidemiology. To understand and estimate the likelihood of resistance spreading in high drug-resistant TB incidence settings, we used epidemiological data to develop a mathematical model of Mycobacterium tuberculosis (Mtb) transmission.
Methods
A four-strain (drug-susceptible (DS), isoniazid mono-resistant (INH-R), rifampicin mono-resistant (RIF-R) and multidrug-resistant (MDR)) compartmental deterministic Mtb transmission model was developed to explore the progression from DS- to MDR-TB in The Philippines and Viet Nam. The models were calibrated using data from national tuberculosis prevalence (NTP) surveys and drug resistance surveys (DRS). An adaptive Metropolis algorithm was used to estimate the risks of drug resistance amplification among unsuccessfully treated individuals.
Results
The estimated proportion of INH-R amplification among failing treatments was 0.84 (95% CI 0.79–0.89) for The Philippines and 0.77 (95% CI 0.71–0.84) for Viet Nam. The proportion of RIF-R amplification among failing treatments was 0.05 (95% CI 0.04–0.07) for The Philippines and 0.011 (95% CI 0.010–0.012) for Viet Nam.
Conclusion
The risk of resistance amplification due to treatment failure for INH was dramatically higher than RIF. We observed RIF-R strains were more likely to be transmitted than acquired through amplification, while both mechanisms of acquisition were important contributors in the case of INH-R. These findings highlight the complexity of drug resistance dynamics in high-incidence settings, and emphasize the importance of prioritizing testing algorithms which allow for early detection of INH-R.
Funder
Melbourne Research, University of Melbourne
National Health and Medical Research Council
NHMRC
Publisher
Springer Science and Business Media LLC
Reference54 articles.
1. WHO. Global Tuberculosis Report 2020. https://www.whoint/teams/global-tuberculosis-programme/tb-reports/global-tuberculosis-report-2020. 2020.
2. WHO. WHO consolidated guidelines on drug-resistant tuberculosis treatment. 2019.
3. Ragonnet R, Trauer JM, Denholm JT, Marais BJ, McBryde ES. High rates of multidrug-resistant and rifampicin-resistant tuberculosis among re-treatment cases: where do they come from? BMC Infect Dis. 2017;17(1):36.
4. Trauer JM, Ragonnet R, Doan TN, McBryde ES. Modular programming for tuberculosis control, the “AuTuMN” platform. BMC Infect Dis. 2017;17(1):546.
5. Zwerling A, Shrestha S, Dowdy DW. Mathematical Modelling and Tuberculosis: Advances in Diagnostics and Novel Therapies. Adv Med. 2015;2015:907267.
Cited by
3 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献